Home >> Research Area >>Metabolism>>IDO>> INCB024360 analogue

INCB024360 analogue

potent and selective inhibitor of IDO1 CAS# 914471-09-3

INCB024360 analogue

Catalog No. BCC1647----Order now to get a substantial discount!

Product Name & Size Price Stock
INCB024360 analogue: 5mg $81 In Stock
INCB024360 analogue: 10mg Please Inquire In Stock
INCB024360 analogue: 20mg Please Inquire Please Inquire
INCB024360 analogue: 50mg Please Inquire Please Inquire
INCB024360 analogue: 100mg Please Inquire Please Inquire
INCB024360 analogue: 200mg Please Inquire Please Inquire
INCB024360 analogue: 500mg Please Inquire Please Inquire
INCB024360 analogue: 1000mg Please Inquire Please Inquire
Related Products
  • NLG919

    Catalog No.:BCC2325
    CAS No.:1402836-58-1

Quality Control of INCB024360 analogue

Number of papers citing our products

Chemical structure

INCB024360 analogue

3D structure

Chemical Properties of INCB024360 analogue

Cas No. 914471-09-3 SDF Download SDF
PubChem ID 11978742 Appearance Powder
Formula C9H7ClFN5O2 M.Wt 271.64
Type of Compound N/A Storage Desiccate at -20°C
Solubility DMSO : ≥ 52 mg/mL (191.43 mM)
*"≥" means soluble, but saturation unknown.
Chemical Name (4E)-4-[(3-chloro-4-fluoroanilino)-nitrosomethylidene]-1,2,5-oxadiazol-3-amine
SMILES C1=CC(=C(C=C1NC(=C2C(=NON2)N)N=O)Cl)F
Standard InChIKey MUVQOOPKPBEAJZ-VQHVLOKHSA-N
Standard InChI InChI=1S/C9H7ClFN5O2/c10-5-3-4(1-2-6(5)11)13-9(14-17)7-8(12)16-18-15-7/h1-3,13,15H,(H2,12,16)/b9-7+
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of INCB024360 analogue

DescriptionPotent indoleamine 2,3-dioxygenase (IDO) inhibitor (IC50 values are 19 and 67 nM in enzymatic activity and HeLa cell assays, respectively). Decreases kynurenine levels in plasma and reduces tumor growth in vivo. Cell membrane permeable.

INCB024360 analogue Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

INCB024360 analogue Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of INCB024360 analogue

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.6813 mL 18.4067 mL 36.8134 mL 73.6269 mL 92.0336 mL
5 mM 0.7363 mL 3.6813 mL 7.3627 mL 14.7254 mL 18.4067 mL
10 mM 0.3681 mL 1.8407 mL 3.6813 mL 7.3627 mL 9.2034 mL
50 mM 0.0736 mL 0.3681 mL 0.7363 mL 1.4725 mL 1.8407 mL
100 mM 0.0368 mL 0.1841 mL 0.3681 mL 0.7363 mL 0.9203 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on INCB024360 analogue

INCB024360 analogue is a potent and selective inhibitor of IDO1 with IC50 value of 67 nM. [1]

IDO (indoleamine-pyrrole 2, 3-dioxygenase) is an enzyme which is encoded by the IDO1 gene. IDO is the rate-limiting and first enzyme of tryptophan which is one amino acid of human catabolism through kynurenine pathway. The decrease of L-tryptophan can cause halted growth of T cells as well as microbes. IDO belongs to immunomodulatory enzyme. It is produced by some activated macrophages and immunoregulatory cells. IDO is overexpressed in a wide range of cancer cells such as lung, prostatic, pancreatic, colorectal cancer. It is indentified to help cancer cells to escape the immune system by reducing the level of L-tryptophan in the microenvironment of cells.[2]

In Hela cells, INCB024360 analogue selectively inhibited the activity of human IDO1 with IC50 value of 19 nM. On the other hand, INCB024360 analogue demonstrated little inhibition activity against TDO (tryptophan 2, 3-dioxygenase). In murine B16 cells, INCB024360 analogue inhibited IDO with IC50 value of 46 nM [1].

In naive C57BL/6 mice, 100 mg/kg INCB024360 analogue injected subcutaneously reduced kynurenine levels by >50% via inhibition of IDO activity. In C57BL/6 mice bearing GM-CSF- secreting B16 tumors, INCB024360 analogue (25, 50, and 75 mg/kg b.i.d.) injected subcutaneously for 14 days dose-dependently inhibited tumor growth [1].

References:
[1].  Yue EW1, Douty B, Wayland B, et al. Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model. J Med Chem. 2009 Dec 10;52(23):7364-7.
[2].  Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ: Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003, 9(10):1269-1274.

Featured Products
New Products
 

References on INCB024360 analogue

Structural insights into the binding mechanism of IDO1 with hydroxylamidine based inhibitor INCB14943.[Pubmed:28412361]

Biochem Biophys Res Commun. 2017 May 27;487(2):339-343.

IDO1 (indoleamine 2, 3-dioxygenase 1), a well characterized immunosuppressive enzyme, has attracted growing attention as a potential target for cancer immunotherapy. Hydroxylamidine compounds INCB024360 and INCB14943 (INCB024360 analogue) are highly effective IDO1 inhibitors. INCB024360 is undergoing clinical trials for treatment of various types of human cancer. Here, we determined the co-crystal structure of IDO1 and INCB14943, and elucidate the detailed binding mode. INCB14943 binds to heme iron in IDO1 protein through the oxime nitrogen. Further analysis also reveals that a halogen bonding interaction between the chlorine atom (3-Cl) of INCB14943 and the sulphur atom of C129 significantly improves the inhibition activity against IDO1. Comparing with the other reported inhibitors, the oxime nitrogen and halogen bond interaction are identified as the unique features of INCB14943 among the IDO1 inhibitors. Thus, our study provides novel insights into the interaction between a small molecule inhibitor INCB14943 and IDO1 protein. The structural information will facilitate future IDO1 inhibitor design.

Cancer Immunotherapy: Selected Targets and Small-Molecule Modulators.[Pubmed:26836578]

ChemMedChem. 2016 Mar 4;11(5):450-66.

There is a significant amount of excitement in the scientific community around cancer immunotherapy, as this approach has renewed hope for many cancer patients owing to some recent successes in the clinic. Currently available immuno-oncology therapeutics under clinical development and on the market are mostly biologics (antibodies, proteins, engineered cells, and oncolytic viruses). However, modulation of the immune system with small molecules offers several advantages that may be complementary and potentially synergistic to the use of large biologicals. Therefore, the discovery and development of novel small-molecule modulators is a rapidly growing research area for medicinal chemists working in cancer immunotherapy. This review provides a brief introduction into recent trends related to selected targets and pathways for cancer immunotherapy and their small-molecule pharmacological modulators.

Challenges and Opportunities in the Discovery of New Therapeutics Targeting the Kynurenine Pathway.[Pubmed:26207924]

J Med Chem. 2015 Nov 25;58(22):8762-82.

The kynurenine pathway is responsible for the metabolism of more than 95% of dietary tryptophan (TRP) and produces numerous bioactive metabolites. Recent studies have focused on three enzymes in this pathway: indoleamine dioxygenase (IDO1), kynurenine monooxygenase (KMO), and kynurenine aminotransferase II (KAT II). IDO1 inhibitors are currently in clinical trials for the treatment of cancer, and these agents may also have therapeutic utility in neurological disorders, including multiple sclerosis. KMO inhibitors are being investigated as potential treatments for neurodegenerative diseases, such as Huntington's and Alzheimer's diseases. KAT II inhibitors have been proposed in new therapeutic approaches toward psychiatric and cognitive disorders, including cognitive impairment associated with schizophrenia. Numerous medicinal chemistry studies are currently aimed at the design of novel, potent, and selective inhibitors for each of these enzymes. The emerging opportunities and significant challenges associated with pharmacological modulation of these enzymes will be explored in this review.

Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model.[Pubmed:19507862]

J Med Chem. 2009 Dec 10;52(23):7364-7.

A hydroxyamidine chemotype has been discovered as a key pharmacophore in novel inhibitors of indoleamine 2,3-dioxygenase (IDO). Optimization led to the identification of 5l, which is a potent (HeLa IC(50) = 19 nM) competitive inhibitor of IDO. Testing of 5l in mice demonstrated pharmacodynamic inhibition of IDO, as measured by decreased kynurenine levels (>50%) in plasma and dose dependent efficacy in mice bearing GM-CSF-secreting B16 melanoma tumors.

Description

IDO5L is a potent indoleamine 2,3-dioxygenase (IDO) inhibitor with an IC50 of 67 nM.

Keywords:

INCB024360 analogue,914471-09-3,Natural Products,IDO, buy INCB024360 analogue , INCB024360 analogue supplier , purchase INCB024360 analogue , INCB024360 analogue cost , INCB024360 analogue manufacturer , order INCB024360 analogue , high purity INCB024360 analogue

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: